Bespak launched its 2025 ESG Report highlighting advancements in operations, value chain, and sustainability.
Published
Signal category
Research & Knowledge
Quote
“We're proud to launch our 2025 ESG Report.”
— Bespak team
Company
Bespak
Bespak is a global contract development and manufacturing organisation (CDMO) focused on inhaled and nasal drug delivery
- Industry
- Pharmaceutical Manufacturing
- Location
- Holmes Chapel, GB
- Company size
- 622 employees
Bespak is a global contract development and manufacturing organisation (CDMO) focused on inhaled and nasal drug delivery devices and drug-device combination products. Bespak develops and manufactures finished pharmaceutical products, as well as being a leading global supplier of drug delivery devices and componentry to the pharmaceutical industry. With a long history in the development and commercial supply of pressurised Metered Dose Inhalers (pMDIs), Bespak supplies a major proportion of the world’s pMDI dosing valves and actuators, and also specialises in the industrialisation and high-volume manufacture of complex dry powder inhaler (DPI) devices. Headquartered in Holmes Chapel, UK, the company’s service offering spans early-stage feasibility, analytical and product development, through pilot-scale, clinical and commercial-scale drug product fill-finish, to device and component manufacturing.
Founded 1959